Tatiana A Bogush1, Anna A Basharina1, Elena A Bogush2, Alexander M Scherbakov3, Mikhail M Davydov2, Vyacheslav S Kosorukov4. 1. Group of Molecular Tumor Markers, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. 2. Department of Oncology, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation. 3. Laboratory of Oncoproteomics, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation. alex.scherbakov@gmail.com. 4. Laboratory of Transgenic Drugs, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow, Russian Federation.
Abstract
Estrogens play an extremely important role in regulating the proliferation of ovarian cancer. The estrogen receptor alpha (ERα) stimulates cell growth, whereas ERβ can be attributed to tumor suppressors. The study aims to assess the relationship between the expression of estrogen receptors in tumors and the efficacy of front-line platinum plus taxane chemotherapy in ovarian cancer patients. MATERIALS AND METHODS: ERα and ERβ tumor expression was evaluated quantitatively by flow cytometry in a narrowly defined group (31 patients): stage III high-grade serous ovarian carcinoma (HGSOC), suboptimal surgical cytoreduction, front-line platinum plus taxane chemotherapy (front-line, six cycles). RESULTS: The median of progression-free survival (PFS) was 2 times greater (18 vs 8 months, p = 0.04) and the recurrence risk (HR) was 2.2 times (95 % CI: 1.1-6.2, p = 0.04) lower in the group with high (in more than 40% of the cells) vs low level of ERβ tumor expression. The statistically significant difference between PFS in the groups with high vs low tumor ERα expression was not revealed. CONCLUSION: A high level of ERβ and not ERα expression can predict the efficacy of front-line platinum plus taxane chemotherapy in stage III HGSOC patients. The status of estrogen receptor beta can be considered as one of the possible predictors for evaluating the effectiveness of ovarian cancer therapy.
Estrogens play an extremely important role in regulating the proliferation of ovarian cancer. The estrogen receptor alpha (ERα) stimulates cell growth, whereas ERβ can be attributed to tumor suppressors. The study aims to assess the relationship between the expression of estrogen receptors in tumors and the efficacy of front-line platinum plus taxane chemotherapy in ovarian cancer patients. MATERIALS AND METHODS: ERα and ERβ tumor expression was evaluated quantitatively by flow cytometry in a narrowly defined group (31 patients): stage III high-grade serous ovarian carcinoma (HGSOC), suboptimal surgical cytoreduction, front-line platinum plus taxane chemotherapy (front-line, six cycles). RESULTS: The median of progression-free survival (PFS) was 2 times greater (18 vs 8 months, p = 0.04) and the recurrence risk (HR) was 2.2 times (95 % CI: 1.1-6.2, p = 0.04) lower in the group with high (in more than 40% of the cells) vs low level of ERβ tumor expression. The statistically significant difference between PFS in the groups with high vs low tumor ERα expression was not revealed. CONCLUSION: A high level of ERβ and not ERα expression can predict the efficacy of front-line platinum plus taxane chemotherapy in stage III HGSOC patients. The status of estrogen receptor beta can be considered as one of the possible predictors for evaluating the effectiveness of ovarian cancer therapy.
Authors: Amanda N Fader; Jennifer Bergstrom; Amelia Jernigan; Edward J Tanner; Kara Long Roche; Rebecca L Stone; Kimberly L Levinson; Stephanie Ricci; Stephanie Wethingon; Tian-Li Wang; Ie-Ming Shih; Bin Yang; Gloria Zhang; Deborah K Armstrong; Stephanie Gaillard; Chad Michener; Robert DeBernardo; Peter G Rose Journal: Gynecol Oncol Date: 2017-07-30 Impact factor: 5.482
Authors: Susanne Schüler-Toprak; Christoph Moehle; Maciej Skrzypczak; Olaf Ortmann; Oliver Treeck Journal: BMC Cancer Date: 2017-05-08 Impact factor: 4.430
Authors: Kristina Lindemann; Emma Gibbs; Elisabeth Åvall-Lundqvist; Rene dePont Christensen; Kathrine Woie; Marten Kalling; Annika Auranen; Seija Grenman; Thomas Hoegberg; Per Rosenberg; Tone Skeie-Jensen; Elisabet Hjerpe; Anne Dørum; Val Gebski; Gunnar Kristensen Journal: Br J Cancer Date: 2017-01-24 Impact factor: 7.640
Authors: Yi He; Salvador Alejo; Prabhakar Pitta Venkata; Jessica D Johnson; Ilanna Loeffel; Uday P Pratap; Yi Zou; Zhao Lai; Rajeshwar R Tekmal; Edward R Kost; Gangadhara R Sareddy Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208